Company news
Coya Therapeutics, Inc. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Coya Therapeutics, Inc. Announces Positive Results from a Proof-of-Concept Academic Clinical Study for COYA 302 in Amyotrophic Lateral Sclerosis (ALS)
March 20, 2023
Coya Therapeutics, Inc. Announces an Agreement with Dr. Reddy’s Laboratories, Ltd. to License its proposed biosimilar Abatacept for the Development and Commercialization of COYA 302 for the Treatment of Neurodegenerative Diseases
March 19, 2023
Coya Therapeutics to Present ALS Clinical Study Data for its Investigational Biologic Combination at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference.
February 26, 2023
Coya Therapeutics’ Expansion Of Exclusive Worldwide Licensing Agreement With ARscience Biotherapeutics Could Have Outsized Impact On Neurodegenerative And Autoimmune Diseases Treatments
February 15, 2023
Coya Therapeutics, Inc. Announces Expansion of Exclusive Worldwide Licensing Agreement with ARScience Biotherapeutics, Inc. for Development and Commercialization of COYA 301, Coya’s Low-Dose Interleukin 2 (IL-2) Product Candidate
February 14, 2023
Decks
The 5 newest of 24 decks. Every deck is listed under its year.
- Investor Presentation (October 2026)
Investor deck · 25 slides · October 2026
- Investor Presentation (September 2026)
Investor deck · 25 slides · September 2026
- Investor Presentation (August 2026)
Investor deck · 25 slides · August 2026
- Investor Presentation (July 2026)
Investor deck · 18 slides · July 2026
- Investor Presentation (June 2026)
Investor deck · 36 slides · June 2026